VivoSeq
Other

Urinary Retention

30

Pipeline Programs↗

12

Active Trials↗

15

Companies Involved↗

Urinary retention is an emerging landscape with 30 programs across 15 companies. The most active players are Eisai, Roche, Merck & Co.. 12 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

15/100

Mech. Concentration

18/100

Completion Rate

55/100

Attrition Rate

28/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

1 program

Phase 1Roche logo

Roche

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2A

Advanz Pharma

1 program

Phase 3C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

37 of 38 classified programs — the dominant modality here.

3%ALL OTHERSProtein / enzyme13%

Small molecule leads; the ring shows all 38 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.

Analysis

Trial Status

50

clinical trials

Completed17 · 34%
Terminated13 · 26%
Unknown status7 · 14%
Recruiting7 · 14%
Active, not recruiting3 · 6%
Not yet recruiting1 · 2%
Other2 · 4%

Clinical Trials

Trial Activity

50 trials

Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
Recruiting·—·Phase 2·NCT04597372·154 enrolled
Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial
Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT06262048·60 enrolled
Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery
Recruiting·HHackensack Meridian Health·Phase 1·NCT05657990·46 enrolled
Post-Operative Urinary Retention on Revision Knee Arthroplasty: the Role of Intrathecal Morphine
Recruiting·UUniversity of Toronto·Phase 3·NCT07050277·50 enrolled
Evaluation of the Efficacy of the Addition of Magnesium Sulfate to Morphine on the Occurrence of Acute Urinary Retention Following Epidural Anesthesia for Cesarean Section.
Recruiting·CCHU de Reims·Phase 4·NCT06442995·290 enrolled
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
Recruiting·HHackensack Meridian Health·Phase 1/2·NCT03609580·127 enrolled
To Investigate the Outcomes of Rectus Abdominis Flap Detrusor Myoplasty for Urinary Retention
Recruiting·UUniversity Hospitals Cleveland Medical Center·N/A·NCT07379814·50 enrolled
Effect of IV Dexamethasone on Post-op Urinary Retention After Spinal Anesthesia
Active, not recruiting·—·N/A·NCT07077850·1,084 enrolled
NMBA Reversal and Postoperative Urinary Retention
Active, not recruiting·—·N/A·NCT06948409·70,000 enrolled
Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders
Active, not recruiting·TThe Cleveland Clinic·Phase 1·NCT04232683·100 enrolled
D-FAB-POUR Trial: Dexmedetomidine vs Fentanyl as Adjuvants to Bupivacaine on Postoperative Urinary Retention
Not yet recruiting·TTribhuvan University Teaching Hospital, Institute Of Medicine.·Phase 4·NCT07117565·190 enrolled
Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery
Enrolling by invitation·UUniversity of Missouri-Columbia·Phase 4·NCT05887375·118 enrolled
Acupuncture for Postoperative Urinary Retention After Hemorrhoidectomy: a Randomized Controlled Trial
Completed·—·Phase 2·NCT05898919·92 enrolled
Effect of Tizanidine on Postoperative Urinary Retention After Sacrospinous Suspension
Completed·EEndeavor Health·Phase 3·NCT06258785·20 enrolled
Comparison of Intrathecal Dexmedetomidine Versus Fentanyl as Adjuvants to Bupivacaine on Post-operative Urinary Retention in Knee Joint Arthroscopic Surgeries
Completed·—·Phase 4·NCT05596552·70 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)